Global pharmaceutical industry in decline and innovation lacking
Deloitte pharma study: Drop-off in returns on R&D investments – sharp decline in peak sales per asset Zurich/Geneva, 23 January 2023 https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html
The projected return on investment of the global pharmaceutical industry was down significantly from last year. This was revealed by Deloitte’s annual analysis of 20 of the world’s leading pharmaceutical companies. The average expected return on investment for research and development fell from 6.8 per cent in 2021 to just 1.2 per cent in 2022. The study also showed that forecast peak sales per asset declined by a quarter to around $389 million. The development process for new drugs must therefore be transformed and could be made much more efficient with digital technologies. In addition, Switzerland as a pharma location urgently needs clarity over its relationships with Europe, as well as a roadmap for digitising the health care system. Since 2010, the has been measuring the that the biggest life sciences and biotech companies can expect from assets in late-stage development. For each study, Deloitte analyses a cohort of the top global pharmaceutical companies by R&D spend. The 20 companies in the latest study include the two Swiss giants Novartis and Roche. The complete study , including informative graphs, can be found on the website.